Biology of renal cell carcinoma



Publisher: Springer-Verlag in New York

Written in English
Published: Pages: 275 Downloads: 26
Share This

Subjects:

  • Renal cell carcinoma -- Molecular aspects.,
  • Renal cell carcinoma -- Immunotherapy.,
  • Carcinoma, Renal Cell -- physiopathology.,
  • Carcinoma, Renal Cell -- therapy.,
  • Immunotherapy, Adoptive.,
  • Cytokines -- therapeutic use.,
  • Gene Therapy.
  • Edition Notes

    Includes bibliographical references and index.

    Statement[edited by] Ronald M. Bukowski, James H. Finke, Eric A. Klein.
    ContributionsBukowski, Ronald M., Finke, James H., 1944-, Klein, Eric A., 1955-
    Classifications
    LC ClassificationsRC280.K5 B56 1995
    The Physical Object
    Paginationxii, 275 p. :
    Number of Pages275
    ID Numbers
    Open LibraryOL784117M
    ISBN 100387945032
    LC Control Number95016247

Renal cell carcinoma (RCC) with sarcomatoid differentiation belongs to the most aggressive clinicopathologic phenotypes of RCC. It is characterized by a high propensity for primary metastasis and limited therapeutic options due to its relative resistance to established systemic targeted therapy. Most trials report on a poor median overall survival of 5 to 12 by: 4. Overview: The treatment paradigm in metastatic renal cell carcinoma (mRCC) has evolved over the last 5 years. There are now seven approved targeted therapies against the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The use of targeted therapy, sequences, combinations, and investigational compounds will be discussed. Prognostic and predictive Cited by: 6. Renal cell carcinoma (kidney cancer) is among the 10 most common cancers in both men and women, with percent of patients having metastatic renal cell carcinoma (mRCC) where the cancer has spread to other parts of the body. Typically, renal cell carcinoma is a disease that affects older individuals; average age at diagnosis is Keywords: RCC, Biology, Signal transduction, HIF, mTOR, Angiogenesis. The molecular revolution in renal cell carcinoma. In recent years, we have witnessed a profound revolution in the way we approach and treat renal cell carcinoma (RCC).

  Metastasectomy for mRCC. Renal cell carcinoma (RCC) can metastasize to many different organs and has a variable natural history. It may be rapidly progressive or indolent, requiring no immediate systemic treatment [].Identifiable metastases are present at diagnosis in up to 30% of cases or become apparent years after nephrectomy for clinically localized disease in nearly 40% of : Tala Achkar, Jodi K. Maranchie, Leonard J. Appleman.   INTRODUCTION. Renal cell carcinoma (RCC) is the most frequent renal malignant neoplasm with an incidence of cases per men and women per year and an estimation of new cases in in the US, [] accounting for 90% of kidney cancers [].While 81% of new cases are diagnosed as locorregional disease, the Surveillance, Epidemiology, and End Results (SEER) Cited by: 3.   Renal cell carcinoma, or RCC, is also called hypernephroma, adenocarcinoma of renal cells, or renal or kidney cancer. Learn the causes, symptoms, and diagnosis of : The Healthline Editorial Team. What Is Renal Cell Carcinoma? It's the most common type of kidney gh it’s a serious disease, finding and treating it early makes it more likely that you’ll be cured.

Renal Cell Carcinoma 1st Edition PDF Renal Cell Carcinoma 1st Edition PDF Free Download, Renal Cell Carcinoma 1st Edition PDF, Renal Cell Carcinoma 1st Edition Ebook Content While patients with metastatic renal cell carcinoma (mRCC) are now living longer with improved quality of life, the success of novel therapies for mRCC has created challenges.   Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the proximal convoluted tubule. In the UK, it is the eighth most common cancer among adults, affecting.   Renal Cell Carcinoma: Clinical Management provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of Brand: Humana Press. Renal cell carcinoma (RCC) is a type of kidney cancer. Often, RCC has no initial symptoms. When symptoms and signs appear they include constant back pain, fatigue, anemia, weight loss, intermittent fevers, a lump on the lower back side, and blood in the urine. .

Biology of renal cell carcinoma Download PDF EPUB FB2

Renal cell carcinoma listen (REE-nul sel KAR-sih-NOH-muh) The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine. Also called hypernephroma, renal cell adenocarcinoma, and renal cell cancer.

Introduction: The knowledge about the molecular biology of clear cell renal cell carcinoma (ccRCC) is evolving, and Carbonic Anhydrase type IX (CA-IX) has emerged as a potential prognostic marker.

Biology of Renal Cell Carcinoma presents the proceedings of the Third International Symposium on the Biology of Renal Cell Carcinoma, March This symposium gathers "internationally acclaimed researchers from relevant fields of renal cell carcinoma to present their latest work and to interact on the interpretation of these findings and Format: Paperback.

Renal Cell Carcinoma: Clinical Management provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of.

Buy Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets: Read 1 Books Reviews - 5/5(1). This volume examines every major topic area in the modern era of renal carcinoma biology and treatment.

The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic.

Introduction. Approximately one-third of patients with renal cell carcinoma (RCC) present with metastatic disease, and amongst those patients with localized disease, a substantial proportion will patients with metastatic renal cell carcinoma (mRCC), the landscape of therapy has evolved dramatically over the past decade.

From the reviews: “The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice.

certainly appeal to a wide range of readers interested in the research aspect. Biology of Renal Cell Carcinoma presents the proceedings of the Third International Symposium on the Biology of Renal Cell Carcinoma, March This symposium gathers "internationally acclaimed researchers from relevant fields of renal cell carcinoma to present their latest work and to interact on the interpretation of these findings and direction for subsequent studies.

This text presents the proceedings of the third International Symposium on the Biology of Renal Cell Carcinoma. Topics covered in the areas of molecular biology of.

Clear Cell Renal Cell Carcinoma. Most agents available today for the treatment of advanced ccRCC target the von Hippel-Lindau gene (VHL)/hypoxia-inducible factor (HIF)-pathway. Recent advances in genomics, epigenetics, and cancer metabolomics have revealed alterations in new pathways that may serve as potential targets for future by: Renal cell carcinoma.

Translational biology, personalized medicine and novel therapeutic targets Editor(s) Robert A Figlin, W Kimryn Rathmell, Brian I Rini, editors.

Published by Springer, New York, USA, pp, price $, ISBN: Author: Naveen S. Vasudev, James M. Larkin. Main Biology of Renal Cell Carcinoma. Biology of Renal Cell Carcinoma Ronald M. Bukowski M.D., James H. Finke Ph.D., Eric A. Klein M.D. (auth.) Year: Whether you've loved the book or not, if you give your honest and detailed thoughts then people will find new books that are right for them.

Get this from a library. Biology of Renal Cell Carcinoma. [Ronald M Bukowski; James H Finke; Eric A Klein] -- Biology of Renal Cell Carcinoma presents the proceedings of the Third International Symposium on the Biology of Renal Cell Carcinoma, March This symposium gathers "internationally acclaimed.

Renal cell carcinoma (RCC) is a neoplasm of the renal epithelium and accounts for >90% of kidney cancers. Cancer genomic studies have identified numerous molecular events that lead to RCC and Cited by: Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.

RCC occurrence shows a male predomiance over women with a ratio of Specialty: Oncology. Part of the Oxford American Oncology Library, Renal Cell Carcinoma is a concise handbook that addresses the complex management of patients with mRCC.

The book begins with a review of the epidemiology, pathology, and biology of renal cell carcinoma followed by chapters on specific targeted therapies and managing complications. Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma.

Book Description. This reference brings together all aspects of renal cell carcinoma, and provides a basis for understanding the disease's origin, progression and responses to immunotherapy.;Examining the current status of cytokine, cell-based and chemotherapeutic methods of treatment, this book: discusses the clinical presentation of advanced renal carcinoma and its therapeutic challenges.

What is kidney cancer. The most common type of kidney cancer is called renal cell carcinoma. This cancer forms in the cells lining the small tubules in the kidney that filter waste from the blood and make urine.

An estima Americans were expected to have been diagnosed with kidney cancer and an estima to have died of this cancer in 1 Most people with kidney cancer are.

Summarizing a decade of scientific advance and therapeutic innovation, Renal Tumor offers all physicians treating kidney cancer, as well as researchers, updated information concerning the epidemiology, biology, and treatment of renal cell carcinoma.

Contributors to this book are from all over the world and are experts in their individual fields. They have provided reviews about current. Multiple studies have emerged in recent years to define the biology of both clear cell and non-clear cell renal cell carcinoma (RCC).

In parallel, there have been numerous pivotal trials that have. While patients with metastatic renal cell carcinoma (mRCC) are now living longer with improved quality of life, the success of novel therapies for mRCC has created challenges for practicing oncologists.

Many patients who initially respond to targeted therapies ultimately develop progressive disease due to acquired resistance to these agents.

Part of the Oxford American Oncology Library, Renal Cell Carcinoma is a concise handbook that addresses the complex management of patients with mRCC. The book begins with a review of the epidemiology, pathology, and biology of renal cell carcinoma followed by chapters on specific targeted therapies and managing complications.

Staging of Renal Cell Carcinoma, Wolf Jr 7. Tumor Markers, Mulders 8. Renal Cell Carcinoma in Dialysis and Transplantation, Tebyani and Gritsch Renal Cell Carcinoma: Molecular Genetics and Immunobiology 9.

Basic Biology and Clinical Behaviour of Renal Cell Carcinoma, Pantuck, Zisman, Belldegrun Molecular Cytogenics, Kovacs   Read "Renal Cell Carcinoma Translational Biology, Personalized Medicine, and Novel Therapeutic Targets" by available from Rakuten Kobo.

This book provides a comprehensive look at renal cell carcinoma, exploring its biology as well as current and future mol Brand: Springer New York.

Key words: RCC, Biology, Signal transduction, HIF, mTOR, Angiogenesis The molecular revolution in renal cell carcinoma life, as well as in a life expectancy that approaches In recent years, we have witnessed a profound revolution in the way we approach and treat renal cell carcinoma (RCC).

In a relatively short time (10 years. The field of renal cell cancer has undergone a significant resurgence. This book summarizes up-to-date research and innovative ideas for the future in this rapidly changing field, which encompasses medicine, surgery, radiation oncology, basic science, pathology, radiology, and supportive care.

This book is aimed at the clinician or scientist who has an interest in renal cell cancer, whether Cited by: 7. Summary This reference brings together all aspects of renal cell carcinoma, and provides a basis for understanding the disease's origin, progression and responses to immunotherapy.;Examining the current status of cytokine, cell-based and chemotherapeutic methods of treatment, this book: discusses the clinical presentation of advanced renal carcinoma and its therapeutic challenges; reviews.

Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more thandeaths annually. Globally, the five-year survival rate for those diagnosed with metastatic, or advanced kidney cancer, is percent.

Continue reading →. Product Information. This is an important book which examines renal cell carcinoma. Integrating scientific developments and therapeutic innovations over the past decade, this book offers physicians treating kidney cancer and researchers with latest information related to the epidemiology, biology and treatment of renal cell carcinoma.Causes and symptoms.

Renal cell carcinoma appears to be caused by both genetic and environmental factors. Mutations in chromosome 3 have received special attention as an underlying cause. Men are twice as likely as women to develop this cancer, and the majority of cases are diagnosed in people between 50 and 70 years g is believed to double the risk of developing renal cell carcinoma.Clear-cell RCC is the most frequent form of renal cancer with an incidence of 75%, followed by papillary types I and II tumours (10%), chromophobe tumours (5%), carcinoma of the collecting ducts of Bellini (1%) and other rare types.

1 The genetic alterations of the RCC subtypes have been defined and extensively studied in the hereditary forms Cited by: 1.